Mast Therapeutics (NYSEMKT:MSTX) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $5 and the lowest price target forecast is $1. The average forecast of all the analysts is $2.67 and the expected standard deviation is $2.08.
Other Equity analysts have also commented on the company shares. Maxim Group initiates coverage on Mast Therapeutics (NYSEMKT:MSTX).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Maxim Group announces the price target of $5 per share. The rating by the firm was issued on November 12, 2015.
Mast Therapeutics (NYSEMKT:MSTX): stock turned positive on Thursday. Though the stock opened at $0.472, the bulls momentum made the stock top out at $0.472 level for the day. The stock recorded a low of $0.4452 and closed the trading day at $0.4563, in the green by 1.24%. The total traded volume for the day was 2,987,055. The stock had closed at $0.4507 in the previous days trading.
The company shares have dropped -6.25% from its 1 Year high price. On Sep 30, 2015, the shares registered one year high at $0.60 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.36 and the 200 Day Moving Average price is recorded at $0.34. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the CFO of Mast Therapeutics, Inc., Roberts Brandi had purchased shares worth of $19,000 in a transaction dated on March 26, 2015. A total of 38,000 shares were purchased at a price of $0.5 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).